GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » Growth Rank

Crescita Therapeutics (Crescita Therapeutics) Growth Rank : 1 (As of May. 19, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Growth Rank?

Crescita Therapeutics has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Competitive Comparison of Crescita Therapeutics's Growth Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescita Therapeutics's Growth Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Growth Rank falls into.



Crescita Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescita Therapeutics (Crescita Therapeutics) Business Description

Traded in Other Exchanges
Address
2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.

Crescita Therapeutics (Crescita Therapeutics) Headlines

From GuruFocus

Crescita Acquires Minority Interest in The Best You�

By Business Wire Business Wire 09-07-2021

Crescita Awarded Cannabis Research License from Health Canada

By PRNewswire PRNewswire 01-24-2020

Crescita Announces Filing of New Medical Device License

By PRNewswire PRNewswire 01-21-2021

Crescita Reports First Quarter 2022 Results

By Business Wire Business Wire 05-11-2022

Crescita Reports Second Quarter 2023 Results

By Business Wire 08-09-2023

Crescita Reports Third Quarter 2020 Results

By PRNewswire PRNewswire 11-12-2020

Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid

By Business Wire Business Wire 12-15-2021